Low-dose anti-IgE therapy in patients with atopic eczema with high serum IgE levels.
Belloni
Benedetta
B
Ziai
Mahzad
M
Lim
Annick
A
Lemercier
Brigitte
B
Sbornik
Martin
M
Weidinger
Stephan
S
Andres
Christian
C
Schnopp
Christina
C
Ring
Johannes
J
Hein
Rüdiger
R
Ollert
Markus
M
Mempel
Martin
M
D000328:Adult; D018926:Anti-Allergic Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D000888:Antibodies, Anti-Idiotypic / Q000008:administration & dosage / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D003876:Dermatitis, Atopic / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007073:Immunoglobulin E / Q000097:blood / Q000187:drug effects* / Q000235:genetics; D008297:Male; D008875:Middle Aged; D000069444:Omalizumab; D016896:Treatment Outcome
D018926:Anti-Allergic Agents; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C026408:anti-IgE antibodies; D000069444:Omalizumab; D007073:Immunoglobulin E